I have read and appreciated your 4 articles- I had to go back to 2007 to review the chemistry.
For further analysis it would be interesting to overlay the 2020 and 2021 data. 2020 behaved as expected for a seasonal respiratory virus- mostly done by the spring and the summer was fairly benign. This contrasted with 2021 which demonstrated the unseasonal peaks which you have explained. I had assumed that there was a direct toxic effect of the injections as well- the VAERS post-injection mortality has been widely discussed on Substack.
The Canadian data would be challenging to compare with anywhere else in the world due to the "Mix-and Match" supplies of the various injections, and the somewhat randomly extended inter-administration intervals.
My former colleagues and administration were all enthusiastic about the minimal protective effects you have elucidated, and willfully dismissive of the risks, to the point that they were all eager to have their children injected. Of course prophylaxis and early treatment as you have suggested were mocked and dismissed.
I think my latest post (March 20 on Omicron the best natural vaccine for stimulating HERV-K102 trained innate immunity?) deals with a lot of the issues raised. In slide 2 you will see how the R value for Canada and the US increased (rather than decreased) with 2 dose vaccination and then boosting. It is very clear vaccination impedes natural immunity especially trained innate immunity by HERV-K102. I have added an important note to my IVERMECTIN Universe article this morning that what SARS-CoV-2 and HIV-1 have in common as pandemic (enveloped) RNA viruses is that they both target HERV-K102 particle production by entering the CD14+ CD16+ CCR5+ CD32+ (FCGR2A) monocytes/macrophages in mucosa (ie., the sebocytes) [Shen et al. J Virol 2009]. Of course for SARS-CoV-2 the only way to enter these sebocytes is through ADE and CD32. This explains why the SARS-CoV-2 antibodies correlate with severity and not protection. On the other hand for naive individuals who do not exhibit immunosenescence, there will be quick induction of HERV-K102 envelope antibodies (systemically) which can neutralize SARS-CoV-2 particles and quickly resolve the infection with minimal symptoms.
I have read and appreciated your 4 articles- I had to go back to 2007 to review the chemistry.
For further analysis it would be interesting to overlay the 2020 and 2021 data. 2020 behaved as expected for a seasonal respiratory virus- mostly done by the spring and the summer was fairly benign. This contrasted with 2021 which demonstrated the unseasonal peaks which you have explained. I had assumed that there was a direct toxic effect of the injections as well- the VAERS post-injection mortality has been widely discussed on Substack.
The Canadian data would be challenging to compare with anywhere else in the world due to the "Mix-and Match" supplies of the various injections, and the somewhat randomly extended inter-administration intervals.
My former colleagues and administration were all enthusiastic about the minimal protective effects you have elucidated, and willfully dismissive of the risks, to the point that they were all eager to have their children injected. Of course prophylaxis and early treatment as you have suggested were mocked and dismissed.
I think my latest post (March 20 on Omicron the best natural vaccine for stimulating HERV-K102 trained innate immunity?) deals with a lot of the issues raised. In slide 2 you will see how the R value for Canada and the US increased (rather than decreased) with 2 dose vaccination and then boosting. It is very clear vaccination impedes natural immunity especially trained innate immunity by HERV-K102. I have added an important note to my IVERMECTIN Universe article this morning that what SARS-CoV-2 and HIV-1 have in common as pandemic (enveloped) RNA viruses is that they both target HERV-K102 particle production by entering the CD14+ CD16+ CCR5+ CD32+ (FCGR2A) monocytes/macrophages in mucosa (ie., the sebocytes) [Shen et al. J Virol 2009]. Of course for SARS-CoV-2 the only way to enter these sebocytes is through ADE and CD32. This explains why the SARS-CoV-2 antibodies correlate with severity and not protection. On the other hand for naive individuals who do not exhibit immunosenescence, there will be quick induction of HERV-K102 envelope antibodies (systemically) which can neutralize SARS-CoV-2 particles and quickly resolve the infection with minimal symptoms.